Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stirling Receives Ethics Approval For ImmunoXel Trial
Stirling was contracted for this clinical trial in late January 2010 and patient recruitment has already commenced and will continue through March 2010. The study will be conducted
Stirling was contracted for this clinical trial in late January 2010 and patient recruitment has already commenced and will continue through March 2010. The study will be conducted
Under the terms of the agreement, Basilea will receive an upfront payment of CHF75m and will be eligible to receive up to CHF478m in additional payments on achievement
Intus Healthcare has reached an exclusive distribution agreement with HealthLinx in February 2009 for the distribution of OvPlex in the UK and Republic of Ireland (ROI) with an
Instrumentation Laboratory said that the assay’s liquid, ready-to-use format, with time to results in less than five minutes, provides customers with superior ease of use and efficiency versus
Revovir is a Nucleoside Reverse Transcriptase Inhibitor (NRTI). It exerts anti-hepatitis B virus (HBV) effects by inhibiting DNA polymerase, the enzyme that is necessary for the virus to
Construction work for the greenfield production will start in the third quarter of this year. Over the next two years, Helvoet Pharma intends to spend some EUR14m. The
In the Phase III clinical study conducted over three years with more than 4,000 males ages 16 to 26, the quadrivalent HPV vaccine was 89.4% efficacious in reducing
The patent expands upon the original Posiphen and analog patent that claims composition of matter and use of compounds to lower amyloid-ß precursor protein (APP) and thereby treat
The double-blind, placebo-controlled, dose-escalation H5N1 Phase 1 trials were conducted in approximately 100 healthy volunteers age 18 to 45 at three US clinical sites. The trials were designed
Shire filed a Biologics License Application (BLA) for Replagal in December 2009. The FDA requested additional human pharmacokinetic data to confirm comparability between product that was manufactured in